Tecarfarin, a Novel Vitamin K Reductase Antagonist, Is Not Affected by CYP2C9 and CYP3A4 Inhibition Following Concomitant Administration of Fluconazole in Healthy Participants-Reference-Cited by-同舟云学术

Tecarfarin, a Novel Vitamin K Reductase Antagonist, Is Not Affected by CYP2C9 and CYP3A4 Inhibition Following Concomitant Administration of Fluconazole in Healthy Participants

Published:2011-04 Issue:4 Volume:51 Page:561-574
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Bavisotto Linda M.,Ellis David J.,Milner Peter G.,Combs Daniel L.,Irwin Ian,Canafax Daniel M.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1177/0091270010370588/fullpdf

Reference25 articles.

1. Systematic overview of warfarin and its drug and food interactions;Holbrook;Arch Int Med,2005

2. Interaction of warfarin with drugs, natural substances, and foods;Greenblatt;J Clin Pharmacol,2005

3. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed);Ansell;Chest,2008

4. Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs;Choppin;Br J Pharmacol,2009

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of nivasorexant (ACT‐539313), a selective orexin‐1‐receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects;Pharmacology Research & Perspectives;2023-10

2. Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial;American Journal of Cardiovascular Drugs;2023-01

3. Anticoagulants in Use;Transfusion Practice in Clinical Neurosciences;2022

4. An Overview of Coumarin as a Versatile and Readily Accessible Scaffold with Broad-Ranging Biological Activities;International Journal of Molecular Sciences;2020-06-29

5. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions;Drug Metabolism and Personalized Therapy;2019-05-30